Literature DB >> 3159583

Effect of intravenous ketanserin on plasma catecholamines and renin activity in normal volunteers.

I W Reimann, D Ratge, H Wisser, U Klotz.   

Abstract

In a placebo controlled, single blind, randomized cross over study catecholamines (CA) and renin activity (PRA) in plasma were measured in 2 female and 4 male healthy volunteers, at rest in the supine position, following a single intravenous injection of 0.15 mg/kg ketanserin (K) and placebo (P, 10 ml saline). K caused a significant increase in the area under the plasma norepinephrine (NE) time curve (AUCNE) from 13,200 to 18,100 ng X 1(-1) X min for 1 hour after the injection. The area under the plasma epinephrine (E) time curve (AUCE) was also increased but to a lesser extent; it was significantly elevated from 54 to 68 ng X 1(-1) X min for 1 minute after the injection. Dopamine (DA) and PRA did not show any significant response to ketanserin. Following the P injection, none of the four parameters showed any significant change.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159583     DOI: 10.1007/bf00543323

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

2.  Is ketanserin a D receptor antagonist?

Authors: 
Journal:  Lancet       Date:  1983-03-26       Impact factor: 79.321

3.  Mechanism of antihypertensive action of ketanserin in man.

Authors:  I W Reimann; J C Frölich
Journal:  Br Med J (Clin Res Ed)       Date:  1983-08-06

4.  Pharmacokinetics of ketanserin in man.

Authors:  I W Reimann; P O Okonkwo; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Acute effects of ketanserin on left ventricular function, metabolism and coronary blood flow.

Authors:  J M Walker; P T Wilmshurst; S M Juul; D J Coltart
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

6.  Mechanism of the hypotensive effect of ketanserin.

Authors:  J R Fozard
Journal:  J Cardiovasc Pharmacol       Date:  1982 Sep-Oct       Impact factor: 3.105

7.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

8.  5-hydroxytryptamine and vascular disease.

Authors:  P M Vanhoutte
Journal:  Fed Proc       Date:  1983-02

9.  The effect of ketanserin in essential hypertension.

Authors:  A Anderson; T Morgan; R Dumpys
Journal:  Clin Exp Pharmacol Physiol       Date:  1983 May-Jun       Impact factor: 2.557

10.  Involvement of serotonin in the central regulation of blood pressure: evidence for a facilitating effect on sympathetic nerve activity.

Authors:  R B McCall; S J Humphrey
Journal:  J Pharmacol Exp Ther       Date:  1982-07       Impact factor: 4.030

View more
  1 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.